[go: up one dir, main page]

MX365551B - Proteinas de fusion de apelina y usos de estas. - Google Patents

Proteinas de fusion de apelina y usos de estas.

Info

Publication number
MX365551B
MX365551B MX2015011350A MX2015011350A MX365551B MX 365551 B MX365551 B MX 365551B MX 2015011350 A MX2015011350 A MX 2015011350A MX 2015011350 A MX2015011350 A MX 2015011350A MX 365551 B MX365551 B MX 365551B
Authority
MX
Mexico
Prior art keywords
apelin
domain
fusion polypeptides
fusion proteins
aplnr
Prior art date
Application number
MX2015011350A
Other languages
English (en)
Other versions
MX2015011350A (es
Inventor
Panayiotis Stevis
Gromada Jesper
Murphy Andrew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2015011350A publication Critical patent/MX2015011350A/es
Publication of MX365551B publication Critical patent/MX365551B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un polipéptido o proteína de fusión que comprende un péptido apelina fusionado a un componente de multimerización. La invención también proporciona un polipéptido o proteína de fusión que comprende un péptido apelina fusionado a un dominio Fc, un fragmento de un dominio Fc o una variante de un dominio Fc. Los polipéptidos de fusión Apelina Fc son capaces de unirse al receptor de apelina (APLNR). Los polipéptidos de fusión a apelina Fc pueden activar la APLNR y presentan mejores propiedades farmacocinéticas en comparación con los péptidos apelina que no se fusionan con un Fc o fragmento de Fc. Los polipéptidos de fusión a apelina Fc son útiles en enfermedades y afecciones relacionadas con la función cardiovascular, diabetes, cáncer, obesidad y otras afecciones relacionadas con apelina.
MX2015011350A 2013-03-14 2014-03-14 Proteinas de fusion de apelina y usos de estas. MX365551B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
MX2015011350A MX2015011350A (es) 2016-01-15
MX365551B true MX365551B (es) 2019-06-07

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011350A MX365551B (es) 2013-03-14 2014-03-14 Proteinas de fusion de apelina y usos de estas.

Country Status (15)

Country Link
US (3) US9353163B2 (es)
EP (1) EP2970415B1 (es)
JP (1) JP6525951B2 (es)
KR (1) KR20150127596A (es)
CN (1) CN105026423A (es)
AU (1) AU2014236451B2 (es)
BR (1) BR112015020587A2 (es)
EA (1) EA201591700A1 (es)
ES (1) ES2708957T3 (es)
HK (1) HK1220466A1 (es)
IL (1) IL240587A0 (es)
MX (1) MX365551B (es)
SG (1) SG11201506335YA (es)
WO (1) WO2014152955A1 (es)
ZA (1) ZA201505927B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365551B (es) 2013-03-14 2019-06-07 Regeneron Pharma Proteinas de fusion de apelina y usos de estas.
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
KR20160086942A (ko) 2013-11-20 2016-07-20 리제너론 파아마슈티컬스, 인크. Ａｐｌｎｒ 조절물질 및 이들의 용도
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
US10463716B2 (en) 2014-10-13 2019-11-05 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US20170355734A1 (en) * 2014-12-23 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor
CN107106632A (zh) * 2014-12-29 2017-08-29 中央研究院 一种治疗a型流感病毒感染的方法
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US11340216B2 (en) * 2016-09-13 2022-05-24 Dana-Farber Cancer Institute, Inc. Methods and compositions for the positive selection of protein destabilizers
AU2018240029A1 (en) 2017-03-22 2019-10-17 Research Corporation Technologies, Inc. Engineered stable CH2 polypeptides
JP7001285B2 (ja) * 2017-03-29 2022-01-19 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
WO2018208625A1 (en) * 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
WO2019040390A1 (en) * 2017-08-24 2019-02-28 Phanes Therapeutics, Inc. ANTI-APELIN ANTIBODIES AND USES THEREOF
GB201805675D0 (en) * 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN119613548A (zh) 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
AU2021297998A1 (en) * 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN117065020A (zh) * 2023-02-17 2023-11-17 山东大学 抑制aplnr表达或降低aplnr活性的物质在制备治疗瘢痕药物中的应用
WO2025213190A1 (en) 2024-04-05 2025-10-09 BioAge Labs, Inc. Methods of treating a disease or condition associated with weight gain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991001754A1 (en) 1989-08-09 1991-02-21 Rhodes Buck A Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU2001296023A1 (en) * 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Process for producing peptide
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
WO2005073383A2 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JPWO2007072980A1 (ja) 2005-12-20 2009-06-04 武田薬品工業株式会社 アペリンの新規用途
DK2662449T3 (en) * 2007-05-30 2017-05-15 Postech Academy-Industry- Found immunoglobulin fusion proteins
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP2362878A4 (en) 2008-11-04 2015-09-16 Anchor Therapeutics Inc APJ RECEPTOR COMPOUNDS
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
PL2496691T3 (pl) 2009-11-02 2017-09-29 University Of Washington Terapeutyczne kompozycje nukleazy i sposoby
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
AU2011283694B2 (en) * 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
DK2683360T3 (en) 2011-03-11 2016-05-30 Genzyme Corp PEGYLED APELIN AND APPLICATIONS THEREOF
JPWO2012133825A1 (ja) 2011-03-31 2014-07-28 株式会社 資生堂 ホットフラッシュの抑制剤
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
US9863605B2 (en) * 2011-11-23 2018-01-09 Quarkstar Llc Light-emitting devices providing asymmetrical propagation of light
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
MX365551B (es) 2013-03-14 2019-06-07 Regeneron Pharma Proteinas de fusion de apelina y usos de estas.
KR20160086942A (ko) 2013-11-20 2016-07-20 리제너론 파아마슈티컬스, 인크. Ａｐｌｎｒ 조절물질 및 이들의 용도

Also Published As

Publication number Publication date
CN105026423A (zh) 2015-11-04
EP2970415A1 (en) 2016-01-20
US20160237130A1 (en) 2016-08-18
US20140275489A1 (en) 2014-09-18
AU2014236451A1 (en) 2015-10-15
EP2970415B1 (en) 2018-12-19
HK1220466A1 (zh) 2017-05-05
AU2014236451B2 (en) 2018-08-09
US20180030099A1 (en) 2018-02-01
CA2904731A1 (en) 2014-09-25
WO2014152955A1 (en) 2014-09-25
EA201591700A1 (ru) 2015-12-30
US9353163B2 (en) 2016-05-31
BR112015020587A2 (pt) 2017-10-10
JP2016513733A (ja) 2016-05-16
KR20150127596A (ko) 2015-11-17
JP6525951B2 (ja) 2019-06-05
ZA201505927B (en) 2017-03-29
US9751921B2 (en) 2017-09-05
ES2708957T3 (es) 2019-04-12
IL240587A0 (en) 2015-09-24
MX2015011350A (es) 2016-01-15
SG11201506335YA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
MX365551B (es) Proteinas de fusion de apelina y usos de estas.
MX387180B (es) Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX382848B (es) Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas.
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MY171407A (en) New polypeptides
MX2018011939A (es) Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
ZA202001167B (en) Glucagon-like peptide 1 receptor agonists and uses thereof
PL3265478T3 (pl) Białka fuzyjne zawierające białko wiążące i polipeptyd interleukiny-15 o zmniejszonym powinowactwie wobec IL15Ralfa i ich zastosowania terapeutyczne
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
UA98911C2 (uk) Лікувальні злиття та кон'югати інсулінотропних пептидів з доменним антитілом, що зв'язує сироватковий альбумін
WO2012075318A3 (en) Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
MX2013014008A (es) Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).

Legal Events

Date Code Title Description
FG Grant or registration